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ABSTRACT 
Introduction: Antibodies to glycine receptors (GlyR-Abs) were first defined in progressive 
encephalopathy with rigidity and myoclonus (PERM), but subsequently identified in other clinical 
presentations. We aimed to assess the clinical associations of all patients identified with GlyR-Abs in 
Queensland, Australia between April 2014 to May 2017, and compared these to cases reported in 
the literature.   
Methods: A literature review identified the clinical features of all published GlyR-Ab positive cases 
through online databases. A case series was undertaken via collection of clinical information from all 
patients diagnosed or known to immunology, pathology or neurological services in Queensland 
during the study period of 3 years. 
Results: 187 GlyR-Abs positive cases were identified in the literature. The majority (47.6%) had 
PERM, 22.4% had epilepsy, but the remaining 30% included mixed phenotypes, consisting of 
cerebellar ataxia, movement disorders, demyelination and encephalitis / cognitive dysfunction. By 
contrast, in our series of 14 cases, eight had clinical presentations consistent with seizures and 
epilepsy and only three cases had classical features of PERM. There was one case each of global 
fatiguable weakness with sustained clonus, laryngeal dystonia, and movement disorder with 
hemiballismus and tics.  Rate of response to immune therapy was similar in all groups.  
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Conclusion: GlyR-Abs are linked to a spectrum of neurological disease. The results of the literature 
review and our case series suggest a greater relationship between GlyR-Abs and epilepsy than 
previously reported. 
 
INTRODUCTION: 
The spectrum of neurological disease related to autoantibodies targeting central nervous system 
receptors and regulatory cell surface proteins has been rapidly expanding in the last decade. To 
date, sixteen such targets antigens have been identified, characterized by a wide array of clinical 
syndromes (1). One such target recently identified is the postsynaptic glycine receptor (GlyR) which 
is distributed mainly in the spinal cord, brainstem, and cerebellum. GlyR are also found in human 
hippocampus, but their role is less clear (2).  The GlyR is a glycine-gated chloride ion channel typically 
expressed on the surface of motor neurons in the brainstem and spinal cord, where it regulates 
neuronal excitability. Genetic loss of function results in hereditary hyperekplexia.  
 
Antibodies against GlyR (GlyR-Abs) were first reported in a single case study in 2008 (3). The index 
patient had a severe presentation of progressive encephalomyelitis with rigidity and myoclonus 
(PERM), which responded slowly but impressively to immunotherapy. 
A number of cases of PERM / stiff-person syndrome (SPS) with associated GlyR-Abs were published 
subsequently (4-12). The most comprehensive series to date details 52 patients who were identified 
retrospectively from 779 sera referred to the Oxford Neuroimmunology service from 2008 to 2012 
(13) and included patients from all previous case reports. Seven patients were excluded due to very 
low GlyR-Abs titres. Thirty-three of the remaining 45 were classified as PERM, and two patients had 
more typical SPS. Of the remaining patients, four were described as an epileptic encephalopathy, 
with one case each of recurrent encephalopathy, brainstem encephalitis, ADEM with optic neuritis, 
optic neuritis and cognitive decline.  
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More recently, however, there have been case reports describing GlyR-Abs in patients with epilepsy, 
responsive to immunotherapy in both adults (14, 15) and children (16-18).  In addition, GlyR-Abs 
have been found in retrospective case series of epilepsy patients screened for the presence of anti-
neuronal antibodies (17, 18, 19). These observations, raised questions about the disease associations 
and clinical relevance of GlyR-Abs.  
We conducted a retrospective case series of all patients in Queensland, Australia, found to be 
positive for GlyR-Abs and compare our findings with previously reported cases. 
 
METHODS 
Literature review 
The aim of the literature review was to identify all reported cases of neurological disease associated 
with GlyR-Abs. Cases were identified through a pubmed database search utilising the search strings 
“glycine receptor antibodies” and “glycine receptor encephalitis”. Additional searches were 
undertaken to identify articles related to “glycine”, “PERM”, “stiff-person syndrome” and 
“autoimmune epilepsy”. Reference lists of identified papers were searched to find additional papers 
not captured by the initial search strategy. All identified articles were read in full, with relevant 
information extracted and summarised. 
Case series 
We performed a retrospective chart review of all patients identified as having GlyR-Abs in serum 
and/or CSF. Cases were identified by contacting neurologists working in South East Queensland and 
via case identification through a neuroimmunology laboratory. Patient information was gained 
through the treating clinicians. We reviewed notes, letters, laboratory and electrophysiological 
results as well as neuroimaging and treatment response. All glycine antibody analyses were 
performed by a quaternary reference laboratory, with 13/14 cases using a cell based assay of human 
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embryonic kidney cells (HEK293) transfected to express homomeric alpha1 GlyR subunits 
(Autoimmune Neurology Diagnostic Laboratory (previously Oxford Neuroimmunology service), 
Oxford, UK).  With case 8 an earlier form of the assay was used. Antibody scores (Exponential scale 
from 0-4; 0 negative; >1 positive; 4 very strong) were provided on request. Except where indicated, 
all samples tested negative for all other neuronal cell surface antibodies, including anti-LG1, anti-
CASPR2, anti-AMPA and anti-GABA antibodies. 
Ethical approval for this study was gained through the Queensland Metro South Human Research 
and Ethics Committee (HREC/17/QPAH/249). Informed consent was obtained from all patients or 
next of kin. 
 
RESULTS 
Summary of literature review 
The literature review identified 187 GlyR-Abs positive cases. The results are summarised in Table 1. 
The largest group (47.6% of total) consisted of patients with PERM/SPS. The second most commonly 
reported diagnosis was that of epilepsy (22.4% of total). The remaining 30% were made up of cases 
of cerebellar ataxia, movement disorders, demyelination and cognitive dysfunction. 
The age of onset ranged from 1 to 75 years, with a wide spread in all groups. The mean age of onset 
appeared lower in the epilepsy group (27.1 years) as compared to that of 43.2 years in the PERM / 
SPS group and 40.7 years in the group encompassing the other neurological presentations.  
Abnormal MRI imaging and abnormal EEG results were most common in the epilepsy group.  
Malignancy was most commonly encountered in the group presenting with PERM/SPS. Ten of the 89 
PERM/SPS patients had tumours reported, including 5 thymomas and one case each of marginal B-
cell lymphoma, breast cancer, Hodgkin’s lymphoma and small-cell lung cancer.  Additionally, there 
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were 4 cases with a past history of malignancy (thymoma and lymphoma, malignant melanoma, 
breast cancer and thymoma, Hodgkin’s lymphoma). There were no cases of malignancy in the group 
with epilepsy. One study of 112 patients with opsoclonus-myoclonus reported 9 cases of GlyR-Abs, 
of which 6 were associated with malignancy (4 lung cancer, 1 breast cancer and 1 testicular 
seminoma). 
In the PERM / SPS group, results of 63 out of 89 cases undergoing immunotherapy were reported; of 
these, 24 (38%) showed a partial response and 29 (46%) showed substantial or complete response. 
In the epilepsy group only 12/42 patients had information regarding immunotherapy, but the results 
were similar with 4 (33%) showing a partial response and 7 (58%) a substantial or complete 
response. In the group representing other neurological presentations, only 11/56 cases had 
response to immunotherapy reported, and the results were again similar, with partial response in 5 
(45%) of cases and substantial or complete response in 6 (54%); nine of these patients presented 
with demyelination / inflammation syndromes.  
 
Case series results 
During the period April 2014 to May 2017, 14 cases of positive GlyR-Abs were identified in 
Queensland. The individual cases are described in table 2, with details summarised in table 3. 
The cases were predominantly female with a 11:3 F:M ratio, and an age range of between 20 and 79 
years. Of these, 8 patients presented with epilepsy, 3 patients with PERM/SPS, and the other 
patients suffering from hemiballism/tics, laryngeal dystonia and an atypical neurological syndrome 
comprising of global fatiguable weakness and sustained clonus. 
MRI brain was normal in 6 cases, with a range of abnormalities found in the others (Table 2). CSF 
was obtained in 9 cases, of which 5 were normal and 4 had a high white cell count and/or oligoclonal 
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bands; GlyR antibodies in CSF were tested in 3 patients, of whom 2 were negative. A teratoma was 
detected in one patient, and 2 others had a past history of cancer.  
Immunotherapy was administered in 11/14 patients. In the PERM group, one patient had no 
response, one patient partial and one patient substantial response to immunotherapy. In the “Other 
neurological presentation” group immunotherapy was given to two patients, both had partial or 
good responses. In the epilepsy group, 6 patients received immunotherapy, of whom one had no 
response, one a partial response and 4 substantial responses (Table 2 + 3).  
Patients benefitting best from immunotherapy in the epilepsy group presented with a clinical 
syndrome of an acute encephalitis and refractory status epilepticus, often with other associated 
features. Immunotherapy in those patients usually led to remarkable clinical recovery, even though 
relapses occurred in some patients (Table 2 + 3).  
Two patients followed a more subacute course, where longstanding (>12 months) epilepsy 
worsened without an obvious precipitant. Two further cases had no substantial change to their long-
standing epilepsy prior to detection of GlyR-Ab (Table 2 + 3).  
 
DISCUSSION 
We report the third largest cohort of patients with GlyR-Abs associated neurological disease in the 
literature and the largest series from a defined geographical area and time interval. We found 8 out 
of 14 of our patients suffering with epilepsy, 3 with a presentation consistent with PERM and SPS 
and 3 with a variety of other neurological syndromes. Response to therapy, where undertaken, was 
in general favourable with partial or full resolution of symptoms in 9 out of 11 treated patients. Of 
particular interest is the subgroup of GlyR-Abs positive epilepsy patients refractory to anti-
convulsant therapy, who responded well to immunotherapy. Limitations of our data include the 
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retrospective nature of the presented cases and incomplete characterization of the antibodies with 
regard to titration and CSF antibody status. 
In comparison, a comprehensive review of all reported cases of GlyR-Abs cases to date revealed 
47.6% of cases diagnosed with SPS/PERM, 22.4% of patients suffering from epilepsy with the 
remaining 30% of patients being diagnosed with a wide variety of different syndromes.   
Our results are, therefore, somewhat discrepant with previous literature, with a higher number of 
patients suffering from epilepsy (13, 19). This could partially be explained by the different 
methodologies used for case ascertainment in the two studies. The patients previously studied were 
collated from a quaternary referral laboratory; as GlyR-Abs were at that stage thought to be strongly 
associated with PERM, it is likely that patients referred for testing over the first years of availability 
were preselected for that diagnosis. Epilepsy and encephalopathy were, however, also reported to 
be part of the initial syndrome in 36% of cases in the Carvajal-Gonzalez paper (12). Subsequently, 
other phenotypes were identified in individual patients with seizures (14-18) and in epilepsy 
populations (20, 21).   
This variability of clinical syndromes may be explained by focal breakdown of blood brain barrier, 
allowing entry of peripherally produced antibodies into limited anatomical areas of the CNS. 
Alternatively, this could be explained by antibody specificity to the different GlyR subtypes. Possibly, 
GlyR antibodies could be an epiphenomenon of immunotherapy responsive CNS inflammation 
associated with a pro-epileptic state.  
The GlyR is an inhibitory receptor, consisting of α and β subunits, of which the α-subunit has 4 
different isoforms, giving rise to 4 different GlyR in human adult CNS (22). GlyRα1 receptor is the 
best characterized glycine receptor and was the predominant antigenic target (12); dysfunction of 
the GlyRα1 receptor in brainstem and spinal cord, by mutation, toxic agents (e.g. strychnine) or 
immune mediated, leads to hyperekplexia in humans (3, 23, 24). GlyRα2, 3 and 4 are found more 
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widespread in mammalian CNS, including hippocampus, striatum, cerebellum and cortex (13, 25, 
26). Cross reaction between Glyα1 Ab and the other alpha subunits has been seen in 50% of 
previously reported cases (13). Neuronal hyperexcitability mediated by toxic antibody-mediated 
inhibition of GlyR by strychnine or tranexamic acid has been linked to seizures in animal models and 
historically in humans (27, 28). Although the role of GlyRs in controlling seizures is not clear, GlyR 
agonists have been shown to have an anti-epileptic effect in rat models (29) and in vitro tonic 
inhibition of high affinity hippocampal GlyR leads to epileptiform activity (30).  Thus antibody-
mediated loss of GlyRs (as shown in vitro in (12)) at various sites in the CNS could potentially be a 
cause of epilepsy. 
CONCLUSION: 
Although the neuronal surface antibodies that have been identified to date are described in 
association with specific clinical syndromes, it is becoming clear that, in clinical practice, the 
associations are not always syndrome-specific. It appears that, in addition to the well-established 
connection of GlyR-Abs to SPS and PERM, a subset of patients with refractory epilepsy have 
detectable GlyR-Abs and can respond to immune therapy.  
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Table 1: Summary of all published cases divided into clinical groups 
 
 PERM / SPS group Epileptic seizures group Other Neurological presentation 
Number of cases 89 42 56  
(24 demyelination / inflammatory, 24 
cerebellar ataxia and movement 
disorders, 7 encephalitis, 1 steroid 
responsive deafness) 
Age of onset range (years) 1 – 75 1 - 58 8 - 70 
Mean age of onset (years) 43.18 27.15 40.71 
Male:female ratio (Not 
reported) 
26:24 (39) 15:22 (5) 5:9 (42) 
Number of cases with 
abnormal MRI brain findings  
0 (0%) 10 (24%) 3 (5%) 
Number of cases with 
abnormal EEG findings 
(number of EEGs reported in 
brackets) 
1 (frequent sharp waves) 
(2) 
5 cases with epileptiform 
discharges, 4 cases with 
slowing / encephalopathy (9) 
0 (0) 
Pre-existing other autoimmune 
conditions 
14/89 (16%) 4/42 (10%) 7/56 (13%) 
Prior malignancy 4/89 (4%) 0/42 (0%) 0/56 (0%) 
Malignancy discovered during 
acute presentation 
10/89 (11%) 0/42 (0%) 7/56 (13%)  
No response to immune 
modulation / Died 
10/63 (16 %) 1/12 (9 %) 0/11 (0 %) 
Partial response to 
immunotherapy 
24/63 (38 %) 4/12 (33 %) 5/11 (45 %) 
Substantial / complete 
response to immunotherapy 
29/63 (46 %) 7/12 (58 %) 6/11 (55 %) 
Response to immunotherapy 
not reported / no 
immunotherapy given 
26 30 45 
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Table 2: Summary of GlyR-Abs antibody cases in Queensland over the period from 2014 to 2017 
Num
ber 
Sex Age at 
diagnosis 
GlyR Ab:  
months after 
initial 
assessment  - 
Intensity score 
(0–4) 
Clinical Presentation CSF  analysis MRI brain & EEG 
results 
Tumours newly 
identified or in 
past history 
mRS 
(max) 
Initial 
immunotherapy 
mRS July 
2017 
Current 
immunotherapy 
Relapses and response to 
treatment after GlyR-Abs 
identification and 
immunotherapy  
1 
 
F 29 4 - 0 
12 - 2 
14 - 1.5 
 
Status epilepticus, 
encephalopathy, intubated 
and ventilated 
WCC 2, 
protein 260, 
OCB positive 
MRI brain: normal 
study 
 
EEG: status 
epilepticus, 
subsequent EEGs 
revealed cortical 
dysfunction left 
temporal region 
No tumour 5 IVIG, RTX, MMF 0 IVIG for one year Single seizure  
2 
 
F 20 50 - 4 Status epilepticus, 
intubated & ventilated, 
headache, diplopia, non-
epileptic seizures, 
behavioural change, 
myoclonic jerks affecting 
the upper limbs 
WCC <1, 
protein 340 
MRI brain: normal 
study 
 
EEG: status 
epilepticus, right 
frontocentral focus 
No tumour 5 IVIG, RTX, 
ketogenic diet 
0 RTX Relapse with status 
epilepticus. Nil further 
episodes since rituximab 
treatment 
3 M 57 122 - 4 PERM with startle, 
encephalitis, cognitive 
impairment 
 
WCC <1 
Protein 497,  
MRI brain: normal 
study 
 
Normal EEG 
No tumour 
 
3 IVIG 
 
 
 
1 IVIG IVIG led to improvement in 
hand stiffness 
4 
 
F 37 1 - 1.5 
8 - 2.5 
Acute encephalitis with 
seizures, personality 
change, intubated & 
ventilated 
WCC <1, 
protein 400,  
Abnormal MRI with 
cortical oedema 
(study performed in 
context of ICU 
admission for status 
No tumour 5 IVIG, RTX 1 IVIG No further status 
epilepticus but seizures 
continue monthly 
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epilepticus) 
 
EEG: status 
epilepticus, 
predominantly left 
hemispheric 
5 F 45 1 - 4 
3 - CSF 0 
Hemiballismus / tic disorder 
affecting right-side of body 
WCC 1, 
protein 310, 
OCB positive 
MRI brain:  
Two small triangular 
shaped CSF 
intensity is present 
within the right 
cerebellar 
hemisphere, 
 
EEG: normal 
Past history of 
breast cancer 
2014 and 
melanoma 2016 
2 St, IVIG 2 IVIG Improvement in 
hemiballismus 
 
 
6 F 50 2- 1.5 
6 - 0 
Epilepsy, recurrent status 
epilepticus, cognitive 
impairment 
CSF: not 
tested 
MRI brain: mild 
diffuse atrophy 
 
VEEG: intermittent 
slow left temporal 
and bilateral 
parietal with sharp 
waves left occipital 
region. EEG seizure 
right parietal region. 
No tumour 5 IVIG 1 IVIG  Seizures previously 
weekly, 3 months seizure 
free on IVIG, currently less 
severe seizures every 3 
weeks 
7 
 
F 54 4 - 2 PERM 
Cognitive impairment 
CSF: protein 
270 
MRI brain:  frontal 
and lobe atrophy 
 
EEG: diffuse slowing 
No tumour 5 RTX, St, IVIg 5 Nil. Poor response to immune 
therapy 
8  F 54 60 - 1.5 
60 - CSF 0 
PERM, propriospinal 
myoclonus, seizures, limbic 
CSF: protein 
170, WCC 1 
Normal MRI brain 
 
No tumour 5 PLEX, AZA, St  2 PLEX, St Partial response to PLEX 
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encephalitis Normal EEG 
9 
 
M 68 0 - 4 Seizures, encephalitis, 
memory disturbance 
CSF: not 
tested 
MRI brain:  
increased T2 signal 
bilateral temporal 
lobes   
 
Normal EEG 
No tumour 5 RTX, St, IVIg 2 St Good response of epilepsy 
and encephalitis, ongoing 
amnesia  
10 
 
F 79 0 - 1.5 Laryngeal Dystonia CSF: not 
tested 
MRI brain: normal 
study 
 
EEG: not performed 
Prior NSCLC 1 No treatment 1 Nil  
11 
 
F 31 5- 1.5 
5- CSF 2 
 
 
Global weakness including 
respiratory muscles, 
hyperreflexia, sustained 
clonus, intubation & 
ventilation, memory 
impairment 
CSF 44 WCC, 
100% 
monocytes, 
OCB +’ve, 
Protein 400 
 
MRI brain: normal 
study 
 
EEG: not performed 
Teratoma with 
neural tissue 
 
Also had presence 
of NMDA 
receptor 
antibodies in 
serum and CSF 
and VGKC 
antibodies in 
serum 
 
5 St, IVIG, BSO with 
removal of 
teratoma 
0 Nil Excellent response with 
complete remission of 
symptoms 
12 
 
M 37 10 - 0 
12 - 1.5 
Epilepsy, progressive course 
over 18 months with little 
response to antiepileptic 
medication 
CSF: 15 WCC, 
protein 
normal 
MRI brain: small 
area of cortical 
dysplasia 
 
VEEG: 2 clinical 
seizures comprising 
bilateral hand 
automatisms 
(left>right), 
No tumour 2 St, IVIG 2 IVIg Limited / no response to 
immunotherapy 
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expression of 
disgust, oral 
automatism, left 
arm semi-dystonic 
posturing.  
13 
 
F 39 120 - 3 History of epilepsy since 
adolescence with seizure 
frequency worsening over 
the last 2-3 years 
CSF: not 
tested 
MRI brain: 
hemispheric 
atrophy 
 
EEG: intermittent 
slow regional right 
and left temporal, 
sharp waves right 
anterior temporal, 
EEG seizure left 
parietal region 
No tumour 1 Anticonvulsant 
therapy, no 
immunotherapy 
1 Nil  
14 
 
F 24 240 - 4 Longstanding history of 
epilepsy 
CSF: not 
tested 
MRI brain: normal 
study 
 
EEG: left 
frontotemporal 
spikes 
No tumour  1 Anticonvulsant 
therapy, no 
immunotherapy 
1 Nil  
 
F = female, M = male, CSF = cerebrospinal fluid, WCC = white cell count, OCB = oligoclonal bands, MRI = magnetic resonance imaging, AZA = azathioprine, 
PLEX = plasma exchange, PERM = progressive encephalomyelitis with rigidity and myoclonus, EEG = electroencephalogram, St = steroid therapy, IVIG = 
intravenous immunoglobulins, BSO = bilateral salpingo-oophorectomy, NSCLC = non-small cell lung cancer, RTX = rituximab, MMF = mycophenolate mofetil, 
VEEG = video electroencephalogram, mRS = modified Rankin Scale, GlyR = glycine receptor 
GlyR antibody levels given as exponential scale from 0-4; 0 negative; >1 positive; 4 very strong  
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Table 3: Summary of clinical characteristics of Queensland case series 
 PERM / SPS group Epileptic seizures group Other Neurological 
presentations   
Number of cases 3 8 3 
Age of onset range 
(years) 
55 - 60 20 - 68 31 - 79 
 
Mean age of onset 
(years) 
57.33 38.00 51.66 
Male : female ratio 1:2 2:6 0:3 
Number of cases with 
abnormal MRI findings 
1 5 1 
Number of cases with 
abnormal EEG findings 
(EEGs performed) 
1 (1) 7(8) 0(0) 
Pre-existing other 
autoimmune diseases  
0 0 1 
History of prior 
malignancy 
0 0 2 
Malignancy discovered 
during acute 
presentation 
0 0 1 
No response to immune 
modulation / Died 
1 1 0 
Partial response to 
immunotherapy 
1 1 1 
Substantial / complete 
response to 
immunotherapy 
1 4 1 
Response to 
immunotherapy not 
reported / no 
immunotherapy given 
0 2 1 
 
 
